Your new post is loading...
Your new post is loading...
|
Scooped by
BigField GEG Tech
May 14, 7:31 AM
|
Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.
|
Scooped by
BigField GEG Tech
May 3, 8:42 AM
|
The rise of RNA viruses like SARS-CoV-2 highlights the need for new ways to fight them. RNA-targeting tools like CRISPR/Cas13 are powerful but inefficient in the cytoplasm of cells, where many RNA viruses replicate.
|
Scooped by
BigField GEG Tech
April 30, 6:37 AM
|
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
|
Scooped by
BigField GEG Tech
April 19, 6:13 AM
|
In a remarkable study, researchers have developed a novel CRISPR-Cas9 delivery system utilising cryo-shocked lung tumour cells to target non-small cell lung cancer (NSCLC), particularly those with KRAS mutations. This innovative method, leveraging the concept of synthetic lethality, shows promise in improving the targeting efficiency o
|
Scooped by
BigField GEG Tech
April 10, 7:01 AM
|
RS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the CNIPA in response to an invalidation challenge.
|
Scooped by
BigField GEG Tech
April 5, 6:38 AM
|
Researchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working.
|
Scooped by
BigField GEG Tech
March 19, 6:16 AM
|
A new type of immunotherapy that targets non-cancer cells could help prevent the growth and spread of breast cancer tumors, according to new research funded by Breast Cancer Now.
|
Scooped by
BigField GEG Tech
March 15, 12:54 PM
|
Jan Joseph Melenhorst, PhD, emphasizes how research investigating chronic lymphocytic leukemia biology may result in more targeted CAR T-cell products.
|
Scooped by
BigField GEG Tech
March 1, 6:07 AM
|
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
|
Scooped by
BigField GEG Tech
February 27, 5:03 AM
|
Intellia Therapeutics shares interim clinical results from the Phase 1 portion of the ongoing Phase 1/2 trial of NTLA-2002 in hereditary angioedema (HAE). NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for HAE, and the results were were published online in the Ne
|
Scooped by
BigField GEG Tech
February 21, 6:53 AM
|
The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.
|
Scooped by
BigField GEG Tech
January 24, 9:32 AM
|
BRL-201 had a manageable safety profile and elicited early indications of efficacy in patients with relapsed/refractory non-Hodgkin lymphoma.
|
Scooped by
BigField GEG Tech
January 11, 9:19 AM
|
The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.
|
|
Scooped by
BigField GEG Tech
May 7, 10:43 AM
|
Two blood biomarkers — pre-lymphodepletion C-reactive protein and ferritin — may help predict which patients with lymphoma are at risk for poor outcomes after chimeric antigen receptor T-cell therapy.Investigators from Roswell Park Comprehensive Cancer Center and Moffitt Cancer Center analyzed data from 136 patients with relapsed or refractory diffuse large B-cell lymphoma.
|
Scooped by
BigField GEG Tech
May 2, 9:27 AM
|
Some of the AI-designed gene editors could be more versatile than those found in nature.
|
Scooped by
BigField GEG Tech
April 26, 11:01 AM
|
The FDA approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma. The expanded indication permits treatment with the chimeric antigen receptor T cells after first relapse and applies to adults who are refractory to lenalidomide and have received at least one previous line of therapy, including a proteasome inhibitor and an immunomodulatory
|
Scooped by
BigField GEG Tech
April 17, 6:40 AM
|
Researchers have unveiled a novel method utilising in vivo cleavable donor plasmids for CRISPR-Cas9 and CRISPR-Cas12a, significantly enhancing gene editing efficiency in adult mouse livers. This method employs hydrodynamic delivery of targeting plasmids, showcasing a substantial improvement over traditional techniques.
|
Scooped by
BigField GEG Tech
April 8, 6:38 AM
|
A study aiming to develop a low-cost, rapid detection technique for the widescale detection and screening of oral microorganisms suitable for point-of-care settings was presented at the 102nd General Session of the IADR, which was held in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual Meeting of the Canadian Association for Dental Research, on March 13-16, 2024, in New Orleans, LA, USA.
|
Scooped by
BigField GEG Tech
March 25, 6:13 AM
|
Breakthrough in Brain Cancer Treatment: Dual-Target CAR T Cell Therapy Shows Promise in Early Clinical Trial.
|
Scooped by
BigField GEG Tech
March 18, 10:37 AM
|
A specific gene may play a key role in new treatments that prevent muscle in the body from breaking down in serious muscle diseases, muscular dystrophies.
|
Scooped by
BigField GEG Tech
March 12, 6:19 AM
|
AI tools that can come up with protein structures at the push of a button should be used safely and ethically, say researchers in the field.
|
Scooped by
BigField GEG Tech
February 29, 6:05 AM
|
Belgian researchers from VIB-KU Leuven Center for Microbiology and VIB-UGent Center for Plant Systems Biology have developed a new toolbox of 16 different short DNA sequences that allow triggering controlled and specific recombination events in any genome.
|
Scooped by
BigField GEG Tech
February 23, 8:22 AM
|
Liso-cel sBLAs for indications in relapsed/refractory FL and MCL after exposure to a BTK inhibitor have received priority review from the FDA.
|
Scooped by
BigField GEG Tech
February 20, 6:32 AM
|
|
Scooped by
BigField GEG Tech
January 19, 6:16 AM
|
Researchers at Universidade de São Paulo in Brazil review progress in recent years involving the use of gene editing to cure HIV and prevent associated neurocognitive disorders.
|
Researchers could eventually help develop viable treatments and ultimately a cure for motor neuron disease (MND). They have identified biochemical changes in a protein that is affected by MND. TDP-43 is a protein found in every cell of the body but is particularly important for the health of motor neurons and the brain cells that control voluntary muscle movement. Two research projects have been run, using CRISPR and looking at how TDP-43 proteins become dysfunctional in motor neurons. Researchers found diseased versions of TDP-43 can damage healthy versions of the protein, which may create a cycle of protein dysfunction and degeneration over time. They also discovered that biochemical pathways which control neuron death are triggered early, even before MND symptoms begin. To change the course of the disease, pharmaceutical drugs are needed to be able to prevent neuron death and this TDP-43 protein dysfunction. Researchers are now treating genetically modified mice with MND with different pharmaceutical drugs that specifically target the underlying causes of the disease, and correct the disease mechanism. Their aim is to stop the TDP-43 degenerative cycle and halt the progression of the disease.